XML 30 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Option Plans (Tables)
 12 Months Ended
Dec. 31, 2013
Stock Option Plans [Abstract]  
Allocation of stock based compensation expense
On January 1, 2006, BioTime adopted a new accounting pronouncement, which requires the measurement and recognition for all share-based payment awards made to BioTime’s employees and directors, including employee stock options.  The following table summarizes stock-based compensation expense related to employee and director stock options awards for the years ended December 31, 2013, 2012, and 2011, which was allocated as follows:
 
 
 
Year Ended December 31,
 
All stock-based compensation expense:
 
2013
  
2012
  
2011
 
Research and Development
 
$
829,938
  
$
815,052
  
$
885,581
 
General and Administrative
  
2,214,836
   
1,028,910
   
916,832
 
All stock-based compensation expense included in expenses
 
$
3,044,774
  
$
1,843,962
  
$
1,802,413
 
Schedule of weighted average assumptions to calculate fair value of stock options
The weighted-average estimated fair value of stock options granted during the years ended December 31, 2013 and 2012 was $4.13 per share in both years, using the Black-Scholes Merton model with the following weighted-average assumptions:

 
 
Year Ended
December 31,
 
 
2013
 
2012
 
 
  
 
Expected life (in years)
  
6.68
   
6.35
 
Risk-free interest rates
  
1.51
%
  
1.06
%
Volatility
  
95.22
%
  
98.88
%
Dividend yield
  
0
%
  
0
%
 
Summary of stock option activity
A summary of all option activity under the 2002 Plan and the 2012 Plan for the years ended December 31, 2013, 2012, and 2011, is as follows:

 
 
Options
Available for
Grant
  
Number of
Options
Outstanding
  
Weighted
Average
Exercise
Price
January 31, 2011
  
1,842,168
   
3,320,590
  
$
1.13
 
Granted under 2002 Plan
  
(560,443
)
  
560,443
   
4.89
 
Exercised
  
-
   
(450,660
)
  
0.50
 
Forfeited/expired
  
21,468
   
(21,468
)
  
5.60
 
December 31, 2011
  
1,303,193
   
3,408,905
  
$
2.18
 
Granted under 2002 Plan
  
(280,000
)
  
280,000
   
4.75
 
Granted under 2012 Plan
  
(255,000
)
  
255,000
   
3.45
 
Exercised
  
-
   
(98,541
)
  
2.91
 
Forfeited/expired under 2002 Plan
  
-
   
(164,063
)
  
5.60
 
Added by 2012 Plan (1)
  
4,000,000
   
-
   
-
 
Reduce options ungranted under 2002 Plan (2)
  
(1,023,193
)
  
-
   
-
 
December 31, 2012
  
3,745,000
   
3,681,301
  
$
1.96
 
Granted under 2012 Plan
  
(1,585,000
)
  
1,585,000
   
4.13
 
Exercised
  
-
   
(20,000
)
  
2.30
 
Forfeited/expired under 2002 Plan
  
-
   
(524,166
)
  
4.01
 
Forfeited/expired under 2012 Plan
  
155,000
   
(155,000
)
  
4.18
 
December 31, 2013
  
2,315,000
   
4,567,135
  
$
2.71
 

1)During December 2012, the 2012 Equity Incentive Plan was approved by the BioTime Board of Directors making 4,000,000 common shares available for the grant of options.  This plan was approved by the shareholders during October 2013.
2)During September 2012, the 2002 Plan expired.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Additional information regarding options outstanding
Additional information regarding options outstanding as of December 31, 2013 is as follows:

 
 
Options Outstanding
 
Options Exercisable
 
 
 
  
 
  
 
Range of Exercise
Prices
 
Number
Outstanding 
Weighted Avg.
Remaining
Contractual Life (years)
  
Weighted Avg.
Exercise Price
 
Number
Exercisable 
 
Weighted Avg.
Exercise Price
 
 
 
  
 
  
 
$0.50
  
1,970,400
   
0.77
  
$
0.50
  
1,970,400
  
$
0.50
 
2.30-8.58
  
2,596,735
   
4.86
   
4.39
  
1,277,262
   
4.54
 
$0.50-$8.58
  
4,567,135
   
3.10
  
$
2.71
  
3,247,662
  
$
2.09
 
OncoCyte, OrthoCyte, ReCyte Therapeutics, Cell Cure Neurosciences, LifeMap and BioTime Asia [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Additional information regarding options outstanding
During 2010, BioTime’s subsidiaries OncoCyte, OrthoCyte, ReCyte Therapeutics, and BioTime Asia adopted stock option plans that have substantially the same operative provisions as the BioTime 2002 Stock Option Plan.  The OncoCyte, OrthoCyte and ReCyte Therapeutics stock option plans each authorize the sale of up to 4,000,000 shares of the applicable subsidiary’s common stock through the exercise of stock options or under restricted stock purchase agreements.  The BioTime Asia stock option plan authorizes the sale of up to 1,600 ordinary shares through the exercise of stock options or under restricted stock purchase agreements.  Cell Cure Neurosciences' option plan authorizes the sale of 14,100 ordinary shares through the exercise of stock options.

  
 
Options Outstanding
  
Options Exercisable
 
  
 
  
  
  
 
Range of Exercise
Prices
  
Number
Outstanding 
Weighted Avg.
Remaining
Contractual Life (years)
  
Weighted Avg.
Exercise Price
  
Number
Exercisable 
 
Weighted Avg.
Exercise Price
 
  
 
  
  
  
 
$0.003-$0.75
   
5,256,226
   
5.96
  
$
0.36
   
4,089,035
  
$
0.35
 
1.00-1.75
   
2,072,342
   
5.86
   
1.57
   
571,073
   
1.43
 
2.05-2.34
   
4,080,000
   
6.39
   
2.25
   
1,294,062
   
2.16
 
27.00-42.02
   
7,840
   
6.80
   
37.35
   
7,840
   
37.35
 
$0.003-$42.02
   
11,416,408
   
6.10
  
$
1.28
   
5,962,010
  
$
0.89